•Kansas passes optometry scope of expansion bill for laser procedures•FDA issues third CRL to Aldeyra, rejecting reproxalap NDA•FDA rejects Chiesi Group's NDA for LHON oral drug•High myopes face increased PCO risk with hydrophilic IOLs•ReVision Implant secures FDA Breakthrough Device Designation for visual cortical prosthesis•Kansas passes optometry scope of expansion bill for laser procedures•FDA issues third CRL to Aldeyra, rejecting reproxalap NDA•FDA rejects Chiesi Group's NDA for LHON oral drug•High myopes face increased PCO risk with hydrophilic IOLs•ReVision Implant secures FDA Breakthrough Device Designation for visual cortical prosthesis
HEADLINES
FEATURED
Corneal CXL therapy was approved as the first topical drug therapy not requiring removal of the corneal epithelium for keratoconus treatment.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
